Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase I/II Study With Gemcitabine and RTA 402 or Gemcitabine and Placebo for Patients With Unresectable Pancreatic Cancer

NCT00529113 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00529113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00529113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase I/II Study With Gemcitabine and RTA 402 or Gemcitabine and Placebo for Patients With Unresectable Pancreatic Cancer
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2007
Completion date
November 1, 2009
Enrollment
33 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic neoplasms